Foundation Medicine, a provider of cancer genomic tests and online test data access, has inked a collaboration pact with Johnson & Johnson's ($JNJ) pharma R&D unit to find biomarkers with its test to aid the J&J group's development of cancer drugs. J&J is the fourth pharma to sign up for Foundation's cancer genomic test, which uses next-generation sequencing tech. The company's website also links test data to sources of publicly available information, and its plans include using its website to match patients with appropriate cancer drug trials. Release